Aktiia, a Swiss-US startup that develops optical blood pressure monitors at the wrist, has recently raised €5.6 million in funding. Switzerland-based Redalpine led the round along with strategically recruited international investor syndicate”: Translink Capital, Investiere, Libra, Christian Wenger, Sparks Street Capital, and Barbaric Holdings.
Michael Sidler, co-founder, and Partner of Redalpine say:
Getting blood pressure data 24/7, day and night is a paradigm shift in the daily management of hypertension and will trigger a whole range of novel health- and wellness-related applications.
Back in 2018, the company has raised a €3.7 million funding to bring its idea to life. As per the company claims, the Swiss-US startup is in the final steps of taking its new solution to market with FDA clearance and CE mark pending.
Aktiia was founded in Switzerland in May 2018 out of a passion for creating the best tool for diagnosis and treatment of hypertension. The company’s founders, Mattia Bertschi (CEO) and Josep Solà (CTO), previously contributed to research and development at CSEM, a prestigious Swiss research institute.
For 15 years, they worked day in and day out to understand the language of our heart signals and decode key markers to gain better insight into blood pressure. They built an incredible team of 15 employees and founded Aktiia to turn their years of pioneering work into a useful tool for people around the globe.
The Medtech company’s technology combines common optical sensors and proprietary clinically tested algorithms to measure blood pressure at the wrist. Validated through extensive trials in acute and low-acute settings, its accuracy has received a worldwide acknowledgment, enabling Aktiia to proudly offer the most complete and user-friendly blood pressure companion to date. With one-third of adults globally suffering from hypertension, this mission is more urgent than ever.
Main image credits: Aktiia
Stay tuned to Silicon Canals for more European technology news
